Carolyn Bertozzi, Ph.D.
Professor of Chemistry, Stanford University
Investigator, Howard Hughes Medical Institute
Chair, Lycia Scientific Advisory Board
Carolyn Bertozzi, Ph.D. is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, the Director of Stanford’s Sarafan ChEM-H Institute, and an Investigator of the Howard Hughes Medical Institute. In 2022, Professor Bertozzi received the Nobel Prize in Chemistry for founding the field of bioorthogonal chemistry, a set of chemical reactions that allow researchers to study molecules and their interactions in living things without interfering with natural biological processes.
Professor Bertozzi has co-founded eight companies advancing her work and other approaches for therapeutic application and has previously served on the scientific advisory boards for GlaxoSmithKline and several other biotech companies. She currently serves on the Board of Directors for Alnylam Pharmaceuticals and OmniAb and previously served on Eli Lilly and Company’s Board of Directors from 2017 to 2021.
Professor Bertozzi is an elected member of the Institute of Medicine, National Academy of Sciences, and the American Academy of Arts and Sciences and has been awarded the Lemelson-MIT Prize, the Heinrich Wieland Prize and a MacArthur Foundation Fellowship, among many others. She completed her B.S. in Chemistry from Harvard University and her Ph.D. in Chemistry from the University of California, Berkeley.